Verification register Bio, Health & Neuro
Current reading
The readiness gap, in one scan
AI-assisted assembly · derived results
- Claimed
- 90
- Reported
- 86
- Verified
- 77
- Gap
- +13
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed minus verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-06-28
Adopt with guardrails
- Why
- Genuinely FDA-approved and commercially deployed (1,000+ patients on adaptive therapy across a 40,000+ Percept installed base) with peer-reviewed long-term efficacy (98% continuation, 91% past one year), but real-world adoption is gated by clinician expertise and per-patient signal viability.
- Next
- Treat as a real, regulated, shipping product; cite FDA/CE approval and ADAPT-PD JAMA Neurology evidence, but flag the programming-expertise burden and the ~16% non-qualifying-signal rate in any maturity claim
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 7
- Tier 1
- 0
- Tier 2
- 2
- Tier 3
- 5
- Supports
- 5
- Contradicts
- 2
- Context
- 0
- Latest observed
- 2025-10-09
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
This is the initial public reading. No earlier readiness change is recorded.